Development of new treatment strategies for HIV -1 infection

Research Project

Project/Area Number	24591486
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Infectious disease medicine
Research Institution	Showa Pharmaceutical University
Principal Investigator	HAMADA Koichi 昭和薬科大学, 薬学部, 助教 (00343070)
Project Period (FY)	2012-04-01 – 2015-03-31
Project Status	Completed (Fiscal Year 2014)
Budget Amount *help	¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000) Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000) Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000) Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Keywords	ＨＩＶ－１ / 潜伏感染 / ＰＩ３Ｋ／ＰＴＥＮ / HIV
Outline of Final Research Achievements	The presence of latent vial infection has prevented the eradication of human immunodeficiency virus (HIV) from infected patients successfully treated with anti-retroviral therapy. Combination antiretroviral therapy (cART) can effectively suppress HIV-1 replication, but the latent viral reservoir is impervious to cART and represents a major barrier to curing HIV-1 infection. PI3K/PTEN/GSK-3β pathway is a critical role for cell proliferation and survival. In this study, we identified that PI3K/PTEN/GSK-3β pathway is necessary to HIV infection and reactivation.

Report

(4 results)